サポートされていないブラウザが使用されています。
このサイトの一部の機能が正しく機能しない可能性があります。最適なユーザーエクスペリエンスを得るために、このサイトはChrome、Firefox、Safari、またはEdgeで表示してください。

COVID-19に関する最新情報

RepligenのCOVID-19への対応: 運用状況

Repligenは、生物製剤、ワクチンや診断の開発・製造でお客様が果たす重要な役割を理解したうえで、そのサポートをいたします。一企業として従業員の健康と安全を確保し、弊社の製品およびサービスを世界中のお客様に継続的に提供します。

A cross-functional and multi-site COVID-19 Task Force at Repligen continues to monitor and evaluate the evolving global situation. As a team, we are assessing the latest guidance and facts, and are prioritizing decisions that will protect our employees and ensure that our manufacturing facilities remain open.  If you have specific questions or concerns regarding product supply or technology support, please contact your local Account Manager or our Customer Service team.

 
september 20, 2021 Update

Manufacturing and Operational Status

To date, our manufacturing facilities and distribution centers are fully operational.  We have recently implemented site visitor restrictions, work from home policies for non-operational staff, enhanced facility cleaning procedures, work cell optimization and personal hygiene training to ensure the protection of our employees, manufacturing centers and distribution networks.  These approaches reduce risk of interruption at our manufacturing centers of excellence and distribution centers.

Commercial and Technical Support

We understand that many of our customers are asking us to restrict non-essential visits. Our customer-facing teams are available and enabled to take orders, answer inquiries, and provide support remotely or in person, as allowed, if the situation requires such support. We have defined our global employee travel guidelines to support all customer facing activities.

Employee and Facility Safety

We are implementing precautionary measures to help protect employees and visitors to our sites. Visitors will be notified of required procedures prior to arriving to a site. Signage at entry ways indicate visitor restrictions and procedures. We have implemented employee travel restrictions to all High-risk Level locations (as defined by the CDC) and a self-isolation decision tree to handle travel and potential exposure situations.

Repligen Named Critical Supplier for COVID-19 Vaccine Development

Repligen was recognized as a critical supplier for COVID-19 vaccine development. The team at the Rancho Dominguez Center of Excellence played a vital role in the successful production of over 500 million COVID-19 vaccines for a major manufacturer. We are proud of the part we play in the effort to end the pandemic.

Spectrum®中空糸フィルター

ProConnex®フローパス